tradingkey.logo

Grail Inc

GRAL
View Detailed Chart

35.920USD

-0.690-1.88%
Close 07/17, 16:00ETQuotes delayed by 15 min
1.27BMarket Cap
LossP/E TTM

Grail Inc

35.920

-0.690-1.88%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.88%

5 Days

-17.22%

1 Month

-14.58%

6 Months

+106.20%

Year to Date

+101.23%

1 Year

+81.23%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts
HOLD
Current Rating
40.500
Target Price
10.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Grail Inc
GRAL
4
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
111

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(7)
Neutral(2)
Buy(1)
Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-2.908
Neutral
RSI(14)
36.328
Neutral
STOCH(KDJ)(9,3,3)
11.814
Oversold
ATR(14)
3.178
Low Volatility
CCI(14)
-132.089
Sell
Williams %R
92.137
Oversold
TRIX(12,20)
-0.140
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
38.394
Sell
MA10
41.190
Sell
MA20
44.257
Sell
MA50
41.173
Sell
MA100
36.120
Sell
MA200
28.378
Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Ticker SymbolGRAL
CompanyGrail Inc
CEOMr. Robert (Bob) Ragusa
Websitehttps://grail.com/
KeyAI